Inés Rama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Inés Rama has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
Joan Torras
Nephrology Department, IDIBELL-Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Spain
8 shared publications- Marcella Franquesa
REMAR-IGTP Group Germans Trias i Pujol Research Institute (IGTP) & Nephrology Department, University Hospital Germans Trias i Pujol (HUGTiP), Can Ruti Campus Badalona (Barcelona), Catalonia, Spain
8 shared publications - Nuria Lloberas
Nephrology Department, Hospital Universitari de Bellvitge–IDIBELL, Barcelona, Spain
8 shared publications Josep M. Cruzado
Nephrology Department, Bellvitge University Hospital, IDIBELL. Barcelona, Spain
7 shared publicationsJosep M. Grinyó
Nephrology Department, Bellvitge University Hospital, IDIBELL. Barcelona, Spain
7 shared publicationsJ. Torras
Nephrology Department, IDIBELL, Hospital Universitari de Bellvitge, Barcelona, Spain
6 shared publications
Latest Publications
- Open Access
- 14 June 2022
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 15 (11) , 2046-2055
Effect of kidney replacement therapy modality after first kidney graft failure on second kidney transplantation outcomes
Background: There is a lack of information regarding which is the best dialysis technique after kidney transplant (KT) failure. The aim of this study is to compare the effect of kidney replacement therapy modality-peritoneal dialysis (TX-PD-TX), haemodialysis (TX-HD-TX) and preemptive deceased donor retransplantation (TX-TX) on patient survival and second KT outcomes. Methods: A retrospective observational study from the Catalan Renal Registry was carried out. We included adult patients with failing of their first KT from 2000 to 2018. Results: Among 2045 patients, 1829 started on HD (89.4%), 168 on PD (8.2%) and 48 (2.4%) received a preemptive KT. Non-inclusion on the KT waiting list and HD were associated with worse patient survival. For patients included on the waiting list, the probability of human leucocyte antigens (HLA) sensitization and to receive a second KT was similar in HD and PD. A total of 776 patients received a second KT (38%), 656 in TX-HD-TX, 72 in TX-PD-TX and 48 in TX-TX groups. Adjusted mortality after second KT was higher in TX-HD-TX patients compared with TX-TX and TX-PD-TX groups, without differences between TX-TX and TX-PD-TX groups. Death-censored second graft survival was similar in all three groups. Conclusions: Our results suggest that after first KT failure, PD is superior to HD in reducing mortality in candidates for a second KT without options for preemptive retransplantation.
- 14 June 2022
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 15 (11) , 2046-2055
Open AccessEffect of kidney replacement therapy modality after first kidney graft failure on second kidney transplantation outcomes
Background: There is a lack of information regarding which is the best dialysis technique after kidney transplant (KT) failure. The aim of this study is to compare the effect of kidney replacement therapy modality-peritoneal dialysis (TX-PD-TX), haemodialysis (TX-HD-TX) and preemptive deceased donor retransplantation (TX-TX) on patient survival and second KT outcomes. Methods: A retrospective observational study from the Catalan Renal Registry was carried out. We included adult patients with failing of their first KT from 2000 to 2018. Results: Among 2045 patients, 1829 started on HD (89.4%), 168 on PD (8.2%) and 48 (2.4%) received a preemptive KT. Non-inclusion on the KT waiting list and HD were associated with worse patient survival. For patients included on the waiting list, the probability of human leucocyte antigens (HLA) sensitization and to receive a second KT was similar in HD and PD. A total of 776 patients received a second KT (38%), 656 in TX-HD-TX, 72 in TX-PD-TX and 48 in TX-TX groups. Adjusted mortality after second KT was higher in TX-HD-TX patients compared with TX-TX and TX-PD-TX groups, without differences between TX-TX and TX-PD-TX groups. Death-censored second graft survival was similar in all three groups. Conclusions: Our results suggest that after first KT failure, PD is superior to HD in reducing mortality in candidates for a second KT without options for preemptive retransplantation.
- 1 July 2018
- Published by Wolters Kluwer Health in Transplantation
- Vol. 102 (Supplement) , S521
Effect of Body Weight Variation in Kidney Transplantation
Introduction Obese kidney allograft recipients have an increased risk of surgical complications, delayed graft function(DGF), prolonged hospital stay and late graft failure. However, there is lack of information regarding the effect of body mass index(BMI) variation after kidney transplantation(KT). Methods and Materials In this longitudinal study, we used data from Catalan Renal Registry including first KT recipients within 1990 and 2011. The annual change on post-transplantation BMI was calculated all patient follow-up (until December 2015). Main outcome variables were DGF, eGFR(CKD-EPI), patient and graft survival. Statistical analysis was adjusted for variables impacting on outcome. Results A total of 5,983 kidney trasnplant recipients were included. Obesity was observed in 609 patients(10.9%) at the time of transplantation. Obese patients were transplanted more recently, were younger and received kidneys from younger donors. Incidence of DGF was significantly higher in obese (40.38% vs 29.5%, P7% was associated with worse graft survival. Conclusion Our conclusion is that BMI reduction after KT was not associated with eGFR improvement and only in those with a reduction of >7% patient survival was better with worse long-term graft survival.
- 1 July 2018
- Published by Wolters Kluwer Health in Transplantation
- Vol. 102 (Supplement) , S521
Effect of Body Weight Variation in Kidney Transplantation
Introduction Obese kidney allograft recipients have an increased risk of surgical complications, delayed graft function(DGF), prolonged hospital stay and late graft failure. However, there is lack of information regarding the effect of body mass index(BMI) variation after kidney transplantation(KT). Methods and Materials In this longitudinal study, we used data from Catalan Renal Registry including first KT recipients within 1990 and 2011. The annual change on post-transplantation BMI was calculated all patient follow-up (until December 2015). Main outcome variables were DGF, eGFR(CKD-EPI), patient and graft survival. Statistical analysis was adjusted for variables impacting on outcome. Results A total of 5,983 kidney trasnplant recipients were included. Obesity was observed in 609 patients(10.9%) at the time of transplantation. Obese patients were transplanted more recently, were younger and received kidneys from younger donors. Incidence of DGF was significantly higher in obese (40.38% vs 29.5%, P7% was associated with worse graft survival. Conclusion Our conclusion is that BMI reduction after KT was not associated with eGFR improvement and only in those with a reduction of >7% patient survival was better with worse long-term graft survival.
- 27 September 2017
- Published by Morressier GmbH
Benefit of Peritoneal Dialysis (PD) in the inflammatory state of refractory Chronic Hearth Failure (rCHF)
- 27 September 2017
- Published by Morressier GmbH
Benefit of Peritoneal Dialysis (PD) in the inflammatory state of refractory Chronic Hearth Failure (rCHF)
- 1 May 2017
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 32 (suppl_3) , iii186-iii187
SP242NEPHROLOGY INTERVENTION IN PATIENTS AWAITING CARDIAC SURGERY: A RANDOMISED CONTROLLED TRIAL
- 1 May 2017
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 32 (suppl_3) , iii186-iii187
SP242NEPHROLOGY INTERVENTION IN PATIENTS AWAITING CARDIAC SURGERY: A RANDOMISED CONTROLLED TRIAL
- Open Access
- 1 April 2017
- Published by Elsevier in Data in Brief
- Vol. 11, 221-224
Data on genotypic distribution and linkage disequilibrium of several ANRIL polymorphisms in hemodialysis patients
- 1 April 2017
- Published by Elsevier in Data in Brief
- Vol. 11, 221-224
Open AccessData on genotypic distribution and linkage disequilibrium of several ANRIL polymorphisms in hemodialysis patients
- 1 March 2017
- Published by Elsevier in Clinica Chimica Acta
- Vol. 466, 61-67
Association of ANRIL gene polymorphisms with major adverse cardiovascular events in hemodialysis patients
- 1 March 2017
- Published by Elsevier in Clinica Chimica Acta
- Vol. 466, 61-67
Association of ANRIL gene polymorphisms with major adverse cardiovascular events in hemodialysis patients
- Open Access
- 26 October 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (10) , e0164969
Online Haemodiafiltration Improves Inflammatory State in Dialysis Patients: A Longitudinal Study
Patients undergoing conventional hemodialysis (C-HD) present a greater immuno-inflammatory state probably related to uremia, sympathetic nervous system (SNS) activation and /or membrane bioincompatibility, which could improve with a technique-switching to online hemodiafiltration (OL-HD). The antigen-independent pathway activation of this modified immunologic state turns dendritic cells (DC) into an accurate cell model to study these patients. The aim of this study is to further evaluate the immune-inflammatory state of patients in C-HD assessed by DC maturation. 31 patients were submitted to C-HD and after 4 months switched to the OL-HD technique. Monocytes-derived DCs from HD patients were cultured in the presence of IL-4/GM-CSF. DC-maturation was evaluated by assessing the maturation phenotype by flow cytometry (FACs). DCs-functional capacity to elicit T-cell alloresponse was studied by mixed leucocyte reaction. Cytokine release was assessed by FACs and SNS was evaluated measuring renalase levels by ELISA. An up-regulation of maturation markers was observed in C-HD DCs which induced two fold more T cells proliferation than OL-HD DCs. Also, C-HD-mDCs presented with over-production of pro-inflammatory cytokines (IL-6, IL-1β, IL-8, IL-10 and TNF-α) compared with OL-HD-mDC (P<0·05). Results were correlated with clinical data. When SNS was evaluated, hypotension events and blood pressure were significantly lower and renalase levels were significantly higher after conversion to OL-HD. Diabetes mellitus type 2 patients also found beneficial reduction of mDC when converted to OL-HD compared to non-diabetics. OL-HD could interfere with immuno-inflammatory state in HD patients with an improvement of renalase levels as potential key mediators in the mechanistic pathway of down-regulation of DC maturation.
- 26 October 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (10) , e0164969
Open AccessOnline Haemodiafiltration Improves Inflammatory State in Dialysis Patients: A Longitudinal Study
Patients undergoing conventional hemodialysis (C-HD) present a greater immuno-inflammatory state probably related to uremia, sympathetic nervous system (SNS) activation and /or membrane bioincompatibility, which could improve with a technique-switching to online hemodiafiltration (OL-HD). The antigen-independent pathway activation of this modified immunologic state turns dendritic cells (DC) into an accurate cell model to study these patients. The aim of this study is to further evaluate the immune-inflammatory state of patients in C-HD assessed by DC maturation. 31 patients were submitted to C-HD and after 4 months switched to the OL-HD technique. Monocytes-derived DCs from HD patients were cultured in the presence of IL-4/GM-CSF. DC-maturation was evaluated by assessing the maturation phenotype by flow cytometry (FACs). DCs-functional capacity to elicit T-cell alloresponse was studied by mixed leucocyte reaction. Cytokine release was assessed by FACs and SNS was evaluated measuring renalase levels by ELISA. An up-regulation of maturation markers was observed in C-HD DCs which induced two fold more T cells proliferation than OL-HD DCs. Also, C-HD-mDCs presented with over-production of pro-inflammatory cytokines (IL-6, IL-1β, IL-8, IL-10 and TNF-α) compared with OL-HD-mDC (P<0·05). Results were correlated with clinical data. When SNS was evaluated, hypotension events and blood pressure were significantly lower and renalase levels were significantly higher after conversion to OL-HD. Diabetes mellitus type 2 patients also found beneficial reduction of mDC when converted to OL-HD compared to non-diabetics. OL-HD could interfere with immuno-inflammatory state in HD patients with an improvement of renalase levels as potential key mediators in the mechanistic pathway of down-regulation of DC maturation.
- Open Access
- 1 August 2014
- Published by Taylor & Francis in Pharmacogenomics and Personalized Medicine
- Vol. 7, 251-66
Developments in renal pharmacogenomics and applications in chronic kidney disease
Chronic kidney disease (CKD) has shown an increasing prevalence in the last century. CKD encompasses a poor prognosis related to a remarkable number of comorbidities, and many patients suffer from this disease progression. Once the factors linked with CKD evolution are distinguished, it will be possible to provide and enhance a more intensive treatment to high-risk patients. In this review, we focus on the emerging markers that might be predictive or related to CKD progression physiopathology as well as those related to a different pattern of response to treatment, such as inhibitors of the renin–angiotensin system (including angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers; the vitamin D receptor agonist; salt sensitivity hypertension; and progressive kidney-disease markers with identified genetic polymorphisms). Candidate-gene association studies and genome-wide association studies have analyzed the genetic basis for common renal diseases, including CKD and related factors such as diabetes and hypertension. This review will, in brief, consider genotype-based pharmacotherapy, risk prediction, drug target recognition, and personalized treatments, and will mainly focus on findings in CKD patients. An improved understanding will smooth the progress of switching from classical clinical medicine to gene-based medicine.
- 1 August 2014
- Published by Taylor & Francis in Pharmacogenomics and Personalized Medicine
- Vol. 7, 251-66
Open AccessDevelopments in renal pharmacogenomics and applications in chronic kidney disease
Chronic kidney disease (CKD) has shown an increasing prevalence in the last century. CKD encompasses a poor prognosis related to a remarkable number of comorbidities, and many patients suffer from this disease progression. Once the factors linked with CKD evolution are distinguished, it will be possible to provide and enhance a more intensive treatment to high-risk patients. In this review, we focus on the emerging markers that might be predictive or related to CKD progression physiopathology as well as those related to a different pattern of response to treatment, such as inhibitors of the renin–angiotensin system (including angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers; the vitamin D receptor agonist; salt sensitivity hypertension; and progressive kidney-disease markers with identified genetic polymorphisms). Candidate-gene association studies and genome-wide association studies have analyzed the genetic basis for common renal diseases, including CKD and related factors such as diabetes and hypertension. This review will, in brief, consider genotype-based pharmacotherapy, risk prediction, drug target recognition, and personalized treatments, and will mainly focus on findings in CKD patients. An improved understanding will smooth the progress of switching from classical clinical medicine to gene-based medicine.
- Open Access
- 18 April 2013
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 172 (3) , 444-454
Dendritic cells phenotype fitting under hypoxia or lipopolysaccharide; adenosine 5′-triphosphate-binding cassette transporters far beyond an efflux pump
Summary: This study examines adenosine 5′-triphosphate-binding cassette (ABC) transporters as a potential therapeutic target in dendritic cell (DC) modulation under hypoxia and lipopolysaccharide (LPS). Functional capacity of dendritic cells (DCs) (mixed lymphocyte reaction: MLR) and maturation of iDCs were evaluated in the presence or absence of specific ABC-transporter inhibitors. Monocyte-derived DCs were cultured in the presence of interleukin (IL)-4/granulocyte–macrophage colony-stimulating factor (GM-CSF). Their maturation under hypoxia or LPS conditions was evaluated by assessing the expression of maturation phenotypes using flow cytometry. The effect of ABC transporters on DC maturation was determined using specific inhibitors for multi-drug resistance (MDR1) and multi-drug resistance proteins (MRPs). Depending on their maturation status to elicit T cell alloresponses, the functional capacity of DCs was studied by MLR. Mature DCs showed higher P-glycoprotein (Pgp) expression with confocal microscopy. Up-regulation of maturation markers was observed in hypoxia and LPS-DC, defining two different DC subpopulation profiles, plasmacytoid versus conventional-like, respectively, and different cytokine release T helper type 2 (Th2) versus Th1, depending on the stimuli. Furthermore, hypoxia-DCs induced more B lymphocyte proliferation than control-iDC (56% versus 9%), while LPS-DCs induced more CD8-lymphocyte proliferation (67% versus 16%). ABC transporter-inhibitors strongly abrogated DC maturation [half maximal inhibitory concentration (IC50): P-glycoprotein inhibition using valspodar (PSC833) 5 μM, CAS 115104-28-4 (MK571) 50 μM and probenecid 2·5 μM], induced significantly less lymphocyte proliferation and reduced cytokine release compared with stimulated-DCs without inhibitors. We conclude that diverse stimuli, hypoxia or LPS induce different profiles in the maturation and functionality of DC. Pgp appears to play a role in these DC events. Thus, ABC-transporters emerge as potential targets in immunosuppressive therapies interfering with DCs maturation, thereby abrogating innate immune response when it is activated after ischaemia.
- 18 April 2013
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 172 (3) , 444-454
Open AccessDendritic cells phenotype fitting under hypoxia or lipopolysaccharide; adenosine 5′-triphosphate-binding cassette transporters far beyond an efflux pump
Summary: This study examines adenosine 5′-triphosphate-binding cassette (ABC) transporters as a potential therapeutic target in dendritic cell (DC) modulation under hypoxia and lipopolysaccharide (LPS). Functional capacity of dendritic cells (DCs) (mixed lymphocyte reaction: MLR) and maturation of iDCs were evaluated in the presence or absence of specific ABC-transporter inhibitors. Monocyte-derived DCs were cultured in the presence of interleukin (IL)-4/granulocyte–macrophage colony-stimulating factor (GM-CSF). Their maturation under hypoxia or LPS conditions was evaluated by assessing the expression of maturation phenotypes using flow cytometry. The effect of ABC transporters on DC maturation was determined using specific inhibitors for multi-drug resistance (MDR1) and multi-drug resistance proteins (MRPs). Depending on their maturation status to elicit T cell alloresponses, the functional capacity of DCs was studied by MLR. Mature DCs showed higher P-glycoprotein (Pgp) expression with confocal microscopy. Up-regulation of maturation markers was observed in hypoxia and LPS-DC, defining two different DC subpopulation profiles, plasmacytoid versus conventional-like, respectively, and different cytokine release T helper type 2 (Th2) versus Th1, depending on the stimuli. Furthermore, hypoxia-DCs induced more B lymphocyte proliferation than control-iDC (56% versus 9%), while LPS-DCs induced more CD8-lymphocyte proliferation (67% versus 16%). ABC transporter-inhibitors strongly abrogated DC maturation [half maximal inhibitory concentration (IC50): P-glycoprotein inhibition using valspodar (PSC833) 5 μM, CAS 115104-28-4 (MK571) 50 μM and probenecid 2·5 μM], induced significantly less lymphocyte proliferation and reduced cytokine release compared with stimulated-DCs without inhibitors. We conclude that diverse stimuli, hypoxia or LPS induce different profiles in the maturation and functionality of DC. Pgp appears to play a role in these DC events. Thus, ABC-transporters emerge as potential targets in immunosuppressive therapies interfering with DCs maturation, thereby abrogating innate immune response when it is activated after ischaemia.